ÂÜÀòÂÒÂ×

Dr. Loutit is responsible for global clinical development, and medical and regulatory affairs. Dr. Loutit has 19 years of experience in anti-infective and pulmonary drug development. Prior to Qpex, he was Chief Medical Officer at Mpex, Rempex, and The Medicines Company where he was responsible for the global Phase 1 through 3 clinical development and post-approval studies in the US and/or Europe of inhaled levofloxacin, oritavancin, intravenous minocycline, and meropenem-vaborbactam. Prior to working at these companies, he held positions of increasing responsibility at Intermune overseeing the global clinical development of oritavancin and pirfenidone. He received his medical training at Otago University in New Zealand and completed his Residency in Internal Medicine at Cleveland Metropolitan General Hospital. Following a year as Chief Resident, he completed an Infectious Disease Fellowship at Stanford University, and then joined the Infectious Disease faculty at Stanford, and was Chief of Infectious Disease at the Palo Alto VA Hospital. During this time he was Director of the Infectious Disease Fellowship training program and Assistant Director of the Internal Medicine training program.